Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Edding Genor Group HoldingsHKSE:06998 +0.33%15 Days Payable is 148.31 as of Dec. 2025, which is 1% above its 10-year median of 147.21. GuruFocus rates HKSE:06998 with a GF Score™ of 15/100. The stock has 1 warning sign investors should review. Among 925 Drug Manufacturers companies, Edding Genor Group Holdings ranks better than 75.24% on this metric.
The historical rank and industry rank for Edding Genor Group Holdings's Days Payable or its related term are showing as below:
HKSE:06998'
s Days Payable Range Over the Past 10 Years
Min: 146.11 Med: 147.21 Max: 148.31
Current: 148.31
During the past 2 years, Edding Genor Group Holdings's highest Days Payable was 148.31. The lowest was 146.11. And the median was 147.21.
HKSE:06998's Days Payable is ranked better than 75.24% of 925
companies
in the Drug Manufacturers industry
Industry Median: 88.75
vs HKSE:06998: 148.31
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Edding Genor Group Holdings Days Payable Chart
Edding Genor Group Holdings Annual Data
Trend
Dec24
Dec25
Days Payable
146.11
148.31
Edding Genor Group Holdings Semi-Annual Data
Dec24
Dec25
Days Payable
146.11
148.31
HKSE:06998 vs ZTS: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Edding Genor Group Holdings's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Edding Genor Group Holdings Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Edding Genor Group Holdings's Days Payable distribution charts can be found below:
* The bar in red indicates where Edding Genor Group Holdings's Days Payable falls into.
Edding Genor Group Holdings Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Edding Genor Group Holdings (HKSE:06998) has a Days Payable of 148.31 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Edding Genor Group Holdings and its competitors. This is near median its historical median of 147.21. Over the past decade, Edding Genor Group Holdings' Days Payable has ranged from 146.11 to 148.31. According to the industry distribution chart, Edding Genor Group Holdings ranks #229 out of 925 companies in the Drug Manufacturers industry, placing it in the top 24.8%.
Is Edding Genor Group Holdings' Days Payable too high?
Edding Genor Group Holdings' current Days Payable of 148.31 is near median its 10-year median of 147.21. Over the past 10 years, this metric has ranged from a low of 146.11 to a high of 148.31. The Drug Manufacturers industry median Days Payable is 88.75. Edding Genor Group Holdings' value of 148.31 is 67.1% above this industry median. Based on the distribution chart, Edding Genor Group Holdings ranks #229 out of 925 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Edding Genor Group Holdings has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Edding Genor Group Holdings' Days Payable compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Edding Genor Group Holdings ranks #229 out of 925 companies for Days Payable. This places Edding Genor Group Holdings in the top 25% of its industry — outperforming the majority of peers. The industry median Days Payable is 88.75. Edding Genor Group Holdings' value of 148.31 is 67.1% above this benchmark. Historically, Edding Genor Group Holdings' own Days Payable has ranged from 146.11 to 148.31 over the past decade. While the company's 10-year median is 147.21 vs. the industry median of 88.75, Edding Genor Group Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 88.75, based on 925 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Edding Genor Group Holdings's current Days Payable of 148.31 is 67.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Edding Genor Group Holdings and its competitors. For the Drug Manufacturers industry, the median Days Payable is 88.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Edding Genor Group Holdings's current Days Payable is 148.31, which is near median its own 10-year median of 147.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edding Genor Group Holdings stock overvalued right now?
Edding Genor Group Holdings (HKSE:06998) has a current Days Payable of 148.31. The current Days Payable is 148.31, which is near median its 10-year median of 147.21 and 67.1% above the Drug Manufacturers industry median of 88.75. Edding Genor Group Holdings' overall GF Score™ is 15/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Edding Genor Group Holdings (HKSE:06998), the current Days Payable is 148.31 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Edding Genor Group Holdings Ltd is an integrated specialty biopharmaceutical company, focusing on oncology, autoimmune diseases, cardiovascular diseases, respiratory diseases, and anti-infectives. Through the acquisition of branded drug assets from multinational pharmaceutical companies (MNCs) and licensing in development and commercialisation rights of patented drugs from international biopharmaceutical companies, it has established a portfolio of originator-branded and other drugs. The company has two reportable operating segments: Manufacturing and Distribution, which generates the maximum revenue, and Research and development. Geographically, it derives maximum revenue from the Chinese mainland, and the rest from the USA and other markets.
15GF Score
Get the complete analysis for HKSE:06998
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06998 has been successfully added to your 
